Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Power Processors
- The new Apollo4 Lite and Blue Lite SoCs offer feature-rich capability, optimized memory, powerful graphics performance, and secureSPOT® for robust security in a lightweight solution
- Ideal for digital health applications, such as digital stethoscopes, patient monitoring, and continuous glucose and blood pressure monitoring
- The Apollo4 Blue Lite offers secure Bluetooth® Low Energy connectivity for communication to handheld devices, host equipment, and the Cloud
AUSTIN, Texas, July 10, 2023 (GLOBE NEWSWIRE) -- Ambiq®, a technology leader in ultra-low power semiconductor products and solutions, introduces the Apollo4 Lite and Apollo4 Blue Lite SoC to its expanding portfolio of SoCs for IoT endpoint devices, especially the remote monitoring products of the healthcare sector. This announcement follows Ambiq’s release of its Heart Kit™, an optimized open-source AI model utilizing multi-head neural networks (MH-NNs) to enable a variety of real-time heart-monitoring applications.
The Apollo4 Lite and Blue Lite product line is the latest generation system processor solutions built upon Ambiq’s proprietary Subthreshold Power-Optimized Technology (SPOT®) platform, enabling new features while reducing devices’ overall system power consumption to extend their battery life. Both SoCs are embedded with an ultra-low power Cortex-M4 core that can operate at up to 192 MHz with turboSPOT, an audio subsystem, GPU, and ample MRAM and SRAM. They are also conveniently pin-compatible with Ambiq’s Apollo4 Plus and Blue Plus¹, providing developers with optimum flexibility for innovation.
“Today’s patients are more empowered to monitor and advocate for their own health, and healthcare providers require more data analytics to prescribe holistic treatment,” said David Priscak, VP of Technical Solutions at Ambiq. “With bold graphics and long battery life, state-of-the-art health tracking is now more affordable and accessible thanks to these new additions to our Apollo4 SoC family.”
“The global remote patient market in terms of revenue was estimated to be worth $53.6 billion in 2022 and is poised to reach $175.2 billion by 2027, growing at a CAGR of 26.7% from 2022 to 2027,” said Ms. Anu Dhiman – Lead Healthcare Analyst – MarketsandMarkets Research Pvt. Ltd. “The predominant factors influencing the growth of the market include the benefits of remote patient monitoring to reduce the burden on medical resources, the monitoring benefits of telehealth and remote patient monitoring services, advancements in telecommunications, as increasing geriatric population, and the growing need to expand healthcare access.”
The Apollo4 Lite and the Apollo4 Blue Lite are designed for extended battery life, advanced security, and powerful graphics in small form factors, which are critical for the continued adoption of these devices. Both are now in mass production, targeting digital health products, smartwatches, fitness bands, animal trackers, voice-activated remotes, industrial maintenance, and smart home IoT devices. For more product information, visit www.ambiq.com/apollo4-lite and www.ambiq.com/apollo4-blue-lite.
¹ – Apollo4 Lite is pin-compatible with Apollo4 Plus (AMAP42KP-KBR); Apollo4 Blue Lite is pin-compatible with Apollo4 Blue Plus (AMA4B2KP-KXR.)
Ambiq’s mission is to develop the lowest-power semiconductor solutions to enable intelligent devices everywhere by developing the lowest-power semiconductor solutions to drive a more energy-efficient, sustainable, and data-driven world. Ambiq has helped leading manufacturers worldwide develop products that last weeks on a single charge (rather than days) while delivering a maximum feature set in compact industrial designs. Ambiq’s goal is to take Artificial Intelligence (AI) where it has never gone before in mobile and portable devices, using Ambiq’s advanced ultra-low power system on chip (SoC) solutions. Ambiq has shipped more than 200 million units as of March 2023. For more information, visit www.ambiq.com.
VP of Branding, Marketing, and Investor Relations
Photos accompanying this announcement are available at